Effect of denosumab on renal function in women with osteoporosis evaluated using cystatin C

다국어 초록 (Multilingual Abstract)

Objectives: To investigate renal function during denosumab therapy using the estimated glomerular filtration rate based on cystatin C (eGFRcys) which is more accurate than creatinine (eGFRcr) for renal function.
Methods: Bone mineral densities (BMDs) of lumbar spine and hip regions, eGFRcys, eGFRcr, creatinine clearance (Ccr), and serum total homocysteine (S-Hcy) were measured during 2-year denosumab therapy in 53 women with osteoporosis naïve to anti-osteoporosis drugs (new group) and 64 women who were switched from long-term bisphosphonate treatment to denosumab therapy (switch group).
Results: There were no significant differences in age, eGFRcr, Ccr, eGFRcys, and S-Hcy levels at baseline between the groups. BMDs in the lumbar spine, femoral neck, and total hip increased significantly after 2-year denosumab therapy in both groups. eGFRcr decreased in the switch group, and Ccr decreased in both groups; however, eGFRcys and S-Hcy levels did not change significantly in either group. To investigate the causal factors associated with the decrease in eGFRcr and Ccr, multiple regression analysis was performed in all patients. Denosumab initiation within 3 months after fracture and eGFRcr or Ccr at baseline were independent factors for the decrease in eGFRcr or Ccr during the 2-year denosumab therapy. Decline in creatinine-based renal function could be reflected by increased muscle mass during the ongoing recovery from fracture.
Conclusions: Renal function was preserved in all patients, including those in the switch group during denosumab therapy. Creatinine-based renal function should be cautiously interpreted during denosumab therapy in patients with recent fractures.

참고문헌 (Reference)

1 Barreto EF, "Validation of the sarcopenia index to assess muscle mass in the critically ill : a novel application of kidney function markers" 38 : 1362-1367, 2019

2 Fujiwara S, "Treatment patterns in patients with osteoporosis at high risk of fracture in Japan : retrospective chart review" 13 : 34-, 2018

3 Fischer K, "Timeline of functional recovery after hip fracture in seniors aged 65 and older : a prospective observational analysis" 30 : 1371-1381, 2019

4 Lawson MA, "The pharmacological profile of a novel highly potent bisphosphonate, OX14(1-fluoro-2-(imidazo-[1, 2-a]pyridin-3-yl)-ethyl-bisphosphonate)" 32 : 1860-1869, 2017

5 Arnadottir M, "The effect of reduced glomerular filtration rate on plasma total homocysteine concentration" 56 : 41-46, 1996

6 Dharnidharka VR, "Serum cystatin C is superior to serum creatinine as a marker of kidney function : a meta-analysis" 40 : 221-226, 2002

7 Matsuo S, "Revised equations for estimated GFR from serum creatinine in Japan" 53 : 982-992, 2009

8 Green JR, "Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models" 80 : 225-230, 1997

9 Boonen S, "Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women" 74 : 641-648, 2008

10 Miller PD, "Renal safety in patients treated with bisphosphonates for osteoporosis : a review" 28 : 2049-2059, 2013

11 Cockcroft DW, "Prediction of creatinine clearance from serum creatinine" 16 : 31-41, 1976

12 Pluijm SM, "Practical operationalizations of risk factors for fracture in older women : results from two longitudinal studies" 24 : 534-542, 2009

13 Morley J, "Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink" 31 : 533-545, 2020

14 Yasuda H, "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL" 95 : 3597-3602, 1998

15 Borek DM, "Long-term persistence in patients with osteoporosis receiving denosumab in routine practice : 36-month noninterventional, observational study" 30 : 1455-1464, 2019

16 Yonezawa T, "Influence of the timing of surgery on mortality and activity of hip fracture in elderly patients" 14 : 566-573, 2009

17 Baxmann AC, "Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C" 3 : 348-354, 2008

18 Miller PD, "Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates" 31 : 181-191, 2020

19 Jamal SA, "Effects of denosumab on fracture and bone mineral density by level of kidney function" 26 : 1829-1835, 2011

20 Kendler DL, "Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy" 25 : 72-81, 2010

21 Orimo H, "Diagnostic criteria for primary osteoporosis : year 2000 revision" 19 : 331-337, 2001

22 Araki A, "Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection" 422 : 43-52, 1987

23 Broadwell A, "Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease" 106 : 397-409, 2021

24 Miller PD, "Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates" 101 : 3163-3170, 2016

25 Miyaoka D, "Denosumab improves glomerular filtration rate in osteoporotic patients with normal kidney function by lowering serum phosphorus" 34 : 2028-2035, 2019

26 Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis" 361 : 756-765, 2009

27 Roux C, "Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy : efficacy and safety results from a randomized open-label study" 58 : 48-54, 2014

28 Recknor C, "Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy : a randomized open-label trial" 121 : 1291-1299, 2013

29 Hanley DA, "Denosumab : mechanism of action and clinical outcomes" 66 : 1139-1146, 2012

30 S eronie-Vivien S, "Cystatin C : current position and future prospects" 46 : 1664-1686, 2008

31 Lyu H, "Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use" 104 : 5611-5620, 2019

32 Horio M, "Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan" 61 : 197-203, 2013

33 Hofbauer LC, "Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases" 292 : 490-495, 2004

34 Kobayashi M, "Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis : a retrospective study" 20 : 48-, 2020

35 Ohishi T, "Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients" 42 : 232-240, 2017

36 Francis ME, "Association between serum homocysteine and markers of impaired kidney function in adults in the United States" 66 : 303-312, 2004

37 Tanaka M, "A sol particle homogeneous immunoassay for measuring serum cystatin C" 37 : 27-35, 2004

38 Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation" 40 : 373-383, 1987

39 Dyer SM, "A critical review of the long-term disability outcomes following hip fracture" 16 : 158-, 2016